A ngiogenesis is a fundamental process by which new blood vessels are formed. 1 It has been well recognized that the growth and metastasis of solid tumors requires persistent angiogenesis, and that induction of angiogenesis is a discrete component of the tumor phenotype. 2 This has led to considerable efforts to identify angiogenesis inhibitors that can be used as part of therapeutic strategies to interfere with tumor growth and metastasis. Recently, it was found that there was a positive correlation between expression of the platelet type 12 lipoxygenase (12-LOX) and the progression of human prostate adenocarcinoma and breast cancers. [3] [4] [5] In animal studies, 12-LOX was shown to have no detectable effect on cell growth in vitro but stimulated tumor growth in vivo, and this effect was closely related to increased angiogenesis. 5 12-LOX catalyses the formation of 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE) exclusively from arachidonic acid. 12-HETE has been reported to be involved in a range of biological activities, including induction of angiogenesis. However, the mechanism and pathways involved in the 12-LOXenhanced tumor angiogenesis remain largely unknown.
Ribozymes (Rzs) are RNA molecules that possess enzymatic cleavage activities. They can be designed to target specific RNA sequences. 6 -8 Several features of Rzs make them attractive as potential gene inactivation agents-in particular, their cleavage specificity and their potential ability to cleave multiple substrate molecules. Because of their inherent simplicity and because they can be incorporated into a variety of flanking sequence motifs without changing their site-specific cleavage capacities, the hammerhead and hairpin Rzs have been used in most of the in vitro and in vivo studies to inhibit viruses, 9 -13 suppress oncogenes, 14, 15 and establish transgenic plants. 16 Here, we have designed and constructed a human 12-LOX-specific Rz. Our data showed that the Rz could efficiently cleave its substrate in vitro, an effect that was further confirmed by cleavage using intracellularly expressed Rz RNA. The Rz effect on 12-LOX was examined in a human erythroleukemia (HEL) cell line that displays platelet-like characteristics. 17 The results demonstrate that the Rz can significantly down-regulate the 12-LOX mRNA and inhibit the enzyme activity by 85%. These results provide (a) a basis for further development of Rz-based gene therapy for cancers and cardiovascular diseases and (b) a tool to study the role of 12-LOX in tumor angiogenesis.
MATERIALS AND METHODS

Cell culture
The HEL cell line (TIB 180; American Type Culture Collection, Manassas, Va) was grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Gaithersburg, Md).
Construction of anti-12-LOX Rz
Previous studies have shown that the 5Ј untranslated region, the AUG initiation codon region, and the sequences involved in RNA splicing and polyadenylation appear to be more accessible to antisense oligomers and Rzs. 18 In the present study, therefore, the Rz was designed to target at the first GUC (nucleotide 92) proximal to the AUG codon of the 12-LOX mRNA (Fig. 1A) . 19 The Rz gene, together with a mutant Rz control (mRz), was chemically synthesized and cloned either into a SalI site of pGEM3Zf ϩ vector (Promega, Madison, Wis) for in vitro transcription and cleavage assays or into a SmaI site in the 3Ј untranslated region of neomycin resistance gene (neo) of the pSV2neo vector for expression as a chimeric gene in the HEL cell line (Fig 1B) . The sequence and orientation of the inserts were confirmed by DNA sequencing.
In vitro Rz cleavage
A 25-mer substrate RNA of 12-LOX gene (UCUUCUC-CGGGUCGUAC AACCGCGU) was chemically synthesized for in vitro cleavage assays. The RNA substrate was endlabeled with [␥- 32 P]adenosine triphosphate using T4 polynucleotide kinase in the presence of the ribonuclease inhibitor RNasin (Promega). The Rz and mRz were generated from the T7 promoter of pGEM3Zf ϩ . Cleavage reactions were initiated by preincubating the Rz and substrate at 80°C for 2 minutes, followed by the addition of 5ϫ cleavage buffer (50 mM tris (hydroxymethyl) aminomethane-HCl (pH 7.5), 10 mM MgCl 2 ) and further incubating at 37°C or 50°C for up to 60 minutes. Reactions were stopped by adding formamide loading buffer with ethylene diaminetetraacetic acid, and the cleavage products were fractionated by 20% polyacrylamide gel electrophoresis containing 8 M urea, detected by autoradiography, and then quantitated using a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif).
Transfection of HEL cells
Exponentially growing HEL cells were harvested, washed with phosphate-buffered saline, and resuspended at a density of 1 ϫ 10 7 viable cells per milliliter in RPMI 1640 medium without FBS but containing 10 mM dextrose and 0.1 mM dithiothreitol. Mixtures of 0.4 mL of cell suspension and 10 g of plasmid DNA (double-purified by CsCl 2 ) were subjected to a single pulse of 960 mF, 300 V from a Gene Pulser (BioRad, Hercules, Calif). Cells were then seeded in RPMI 1640 medium supplemented with 10% FBS and incubated for 48 hours. G418 selection (500 g/mL) was further conducted for 2 weeks. The pooled population of stably transfected cells was used in all the assays.
In vitro cleavage activity of neo-Rz chimeric molecule
Cellular mRNAs from HEL cells transfected with pSV2neo-Rz, pSV2neo-mRz, and pSV2neo were extracted using a Quickprep Micro mRNA purification kit (Pharmacia Biotech, Uppsala, Sweden). To determine the activity of neo-Rz chimeric RNA in vitro, mRNAs from HEL cells transfected with pSV2neo-Rz, pSV2neo-mRz, or pSV2neo were each incubated with 32 P-labeled 12-LOX substrate RNA in the Rz cleavage buffer for 2 hours. Gel analyses were performed as described above.
RNA expression analyses
Northern blot analyses were performed for Rz expression and its effect on 12-LOX expression. A total of 2 g of mRNA extracted from the transfected HEL cells was electrophoresed in a 1.6% agarose denaturing gel and transferred onto a nylon membrane. The blots were hybridized either with a 32 P-labeled neo-specific probe and a 32 P-labeled 22-mer oligonucleotide complementary to the Rz catalytic core region for Rz expression study or with a 32 P-labeled 12-LOX-specific probe for measurement of 12-LOX expression, with glyceraldehyde-3-phosphate dehydrogenase as an internal standard.
Measurement of 12-LOX activity
Cells were harvested, washed with phosphate-buffered saline, and resuspended at a density of 1 ϫ 10 7 cells/mL. A total of 0.5 mL of cell suspension was incubated with arachidonic acid (160 mM) and 13-hydroperoxy-9,11-octadecadienoic (5 mM) (activator and internal standard) at 37°C for 10 minutes high-performance liquid chromatography analysis of 12-HETE concentration was performed as described previously. 19 12-LOX activity was expressed as the total amount of 12-HETE accumulated during a 10-munite incubation with arachidonic acid per 10 6 cells. 
RESULTS
In vitro characterization of anti-12-LOX Rz
Based on the strategy of Haseloff and Gerlach, 6 a single hammerhead Rz against the 12-LOX gene was designed as shown in Figure 1 . The Rz was tested for its ability to cleave a synthetic substrate RNA in vitro. Incubation of Rz (100 nM) with substrate in a range of concentrations (100 -3200 nM) resulted in efficient cleavage in a concentration-and time-dependent manner (Figs 2 and 3) . Under multiple turnover conditions, the Rz activity (kcat/K M ) was 0.064 mM Ϫ1 min Ϫ1 at 37°C. An increase in incubation temperature from 37°C to 50°C resulted in a significant improvement in catalytic activity in vitro, with a kcat/K M value of 0.163 mM Ϫ1 min Ϫ1 . The kinetic characteristics of the Rz are summarized in Table 1 .
Expression and cleavage activity of Rz construct in transfected HEL cells To study the in vivo efficiency of the anti-12-LOX Rz, the Rz and its mutant control sequence were cloned into the pSV2neo vector, and the resultant constructs were transfected into HEL cells. After extensive selection in G418, pooled populations of stably transfected cells for each of the constructs were established. To avoid potential clonal variation, only pooled cell populations were used throughout experiments. To confirm expression of the constructs, Northern blot analyses were performed using RNAs from Rz-, mRz-or pSV2neo vector-transfected cells. As shown in Figure 4 , the neomycin mRNA could be detected in all of the transfected cells as expected, but not in the parental HEL cells. When the blot was probed with an antisense oligonucleotide to the active catalytic core, Rz expression was confirmed in Rz-transfected cells. This expression was stable for up to In the vector construct, the Rz was cloned into the 3Ј untranslated region of neomycin gene. To test whether the neo-Rz chimeric RNA produced in cells still maintained Rz catalytic activity, mRNAs were extracted from Rz-, mRz-, or vector-transfected HEL cells that had been incubated with the 32 P-labeled 12-LOX RNA substrate. The results shown in Figure 5 indicate that the neo-Rz mRNA efficiently cleaved the substrate at a rate that was similar to that of in vitro-transcribed Rz.
Down-regulation of 12-LOX gene expression in Rz expressing cells
To analyze the Rz efficiency in cells at a molecular level, Northern blot hybridization was performed to assess the impact of Rz expression on the 12-LOX mRNA level. In Rz-expressing HEL cells, 12-LOX gene expression was markedly suppressed to an undetectable level in the cell cultures at 2 weeks and 6 months, respectively (Fig 6) . In contrast, mRz control-transfected cells had only a marginal impact on 12-LOX expression, which could be due to an antisense effect from the binding arms of the mutant control.
Reduction of 12-LOX activity in Rz-expressing HEL cells
The biological activity of anti-12-LOX Rz in cells was further tested in a high-performance liquid chromatography-based assay in which the 12-LOX catalyzed production of 12-HETE was measured. Incubation of cellular extracts from Rz-transfected cells with arachidonic acid showed a significant reduction in 12-LOX enzyme activity (13%) compared with vector-transfected cells (99%) ( Table 2 ). In mRz-transfected cells, the relative activity of 12-Lox was 8%. Consistent with suppression of the 12-LOX mRNA in Rz-expressing cells (Fig 6) , this result indicated a reduced level of 12-LOX enzyme concentration due to Rz activity.
DISCUSSION
The finding that 12-LOX can enhance angiogenesis and the growth of human prostate and breast cancers has a significant clinical implication on the regulation of tumor progression. In the case of prostate carcinoma, some tumors are extremely malignant with rapid progression, whereas others are localized and dormant for many years. Understanding the mechanism underlying the transition from a latent to a rapidly growing tumor will provide valuable information for clinical management and for the development of cancer therapeutics. To do so, one would need a highly selective method to block the expression or activation of the enzyme. Unfortunately, there are currently no effective inhibitors available for specific inhibition of 12-LOX activity. In the present study, we report a Rz-based approach to inhibit 12-LOX expression. This Rz will also assist in studying the role of 12-LOX in tumor angiogenesis.
We have described results for an anti-12-LOX Rz in the context of a mammalian expression vector. Both the in vitro and in vivo activities of the Rz in this study support the strategy of expressing a Rz from the 3Ј untranslated region of a marker gene in terms of stability and duration of expression. 20 Using a single-base mRz construct as a control, the results indicate that the active catalytic domain of the hammerhead Rz can markedly increase the extent of antisense-mediated inhibition of 12-LOX activity. Gu et al 21 reported a chimeric DNA-RNA hammerhead Rz oligonucleotide that cleaved porcine leukocyte 12-LOX mRNA. They observed that transient transfection of porcine vascular smooth muscle cells with the Rz oligomers caused a dose-dependent decrease in porcine leukocyte-type 12-LOX mRNA levels. However, this effect only lasted for 72 hours due to the fact that a repeated administration is required for oligonucleotide-based approaches for gene inactivation. In our study, Rz efficacy was demonstrated both in vitro and in vivo and lasted for 6 months in tissue culture cells. Thus, this Rz could be a tool to further investigate tumor angiogenesis in animal models. To the best of our knowledge, this is the first report of an effective Rz against the human 12-LOX gene.
To express the Rz in cells, we employed a strategy whereby the Rz was cloned into the 3Ј untranslated region of the neomycin gene in the pSV2neo vector to stabilize Rz in cells. In vitro data showed that the neo-Rz chimeric RNA could cleave the substrate as efficiently as an in vitro-transcribed Rz, indicating that the Rz is stable and the embedded Rz remains active. In expression studies, we observed that the Rz expression was stable for up to 6 months. This may be due to the selection pressure from G418 in culture and to the fact that this gives rise to a high level of the chimeric neo-Rz mRNA that is needed for cell survival. For clinical application of this strategy using chimeric neo-Rz, an efficient transduction of the target cells can be achieved using hightiter viral vector without G418 selection. 22, 23 In summary, this study demonstrates the first example of a specifically designed Rz inhibiting the expression of 12-LOX in HEL cells. Further exploration in animal models, in conjunction with efficient delivery technology, may extend the usefulness of the Rz as an agent for cancer gene therapy.
